CA-MAWI-DNA-TECHNOLOGIES
11.5.2021 15:02:10 CEST | Business Wire | Press release
Mawi DNA Technologies, a biotechnology company focusing on the development of innovative technologies for biosampling, announces that MagBio Genomics has successfully developed an automated RNA purification method for iSWAB-RNA v2 on the Thermofisher KingFisher™ Flex platform with its HighPrep™ Total RNA Isolation Kit - iSWAB™.
Mawi DNA Technologies’ iSWAB-RNA v2 allows for non-invasive self collection, concentration, and stabilization of intact buccal cells and/or any mammalian cells collected with a swab or cytobrush. It enables up to four weeks of real-time ambient stabilization of total RNA from the point of collection to processing. The high-quality RNA extracted from stabilized iSWAB-RNA v2 samples is suitable for gene expression applications such as real-time quantitative PCR, reverse transcription PCR, microarrays, northern blot analysis, nuclease protection assays, cDNA library construction and RNA-seq.
“Collaborating with MagBio Genomics to optimize their HighPrep™ Total RNA Plus Kit-iSWAB™ for iSWAB-RNA v2 was a no-brainer for us, especially because it provides a great option for our high throughput end users like pharma and CROs,” said Dr. Bassam El-Fahmawi, President and CTO, Mawi DNA Technologies. “Partnerships with leaders in nucleic acid purification chemistries with a global presence, such as MagBio Genomics, are increasing worldwide access of our sample collection technologies, which results in better understanding of health and wellness at a global rather than at a regional level.” El-Fahmawi said that due to increased sample sizes in cohort genetic population studies, there is an increasing need for automated RNA purification solutions. The MagBio HighPrep Total RNA Plus Kit-iSWAB™ simplifies this research step, which can be labor-intensive.
“MagBio has successfully developed and optimized the HighPrep™ Total RNA Isolation Kit-iSWAB™ for extraction of total RNA from iSWAB-RNA v2 samples on Thermofisher KingFisher™ Flex Purification System,” said Dr. Mothomang Mlalazi-Oyinloye, Associate Scientific Director, MagBio Genomics. “This new method is being used by a major pharmaceutical company to process iSWAB-RNA v2 samples for elucidation of molecular mechanisms of cancer development. With this automated protocol, 96 samples can be run in less than one hour.” She added that the extracted RNA is of high purity and quality and is compatible with complex and sensitive assays. RNA yields up to 1ug per sample are obtained (Qubit RNA Broad Assay).
“We are expanding our automated methods library to include the most commonly used lab automation systems,” Dr. Mlalazi-Oyinloye said. “iSWAB-RNA v2 is the non-invasive sample collection alternative to venipuncture and tissue biopsy our fellow researchers have been looking for which maintains RNA integrity especially during long transit times. MagBio Genomics is all about making the next generation sequencing workflow better. We developed an automated method for simplifying RNA purification from iSWAB-RNA v2 samples using our HighPrep™ Total RNA Plus Kit-iSWAB™,” said Dr. Hyacinth Ntchobo, CEO, MagBio Genomics. He added that when used in combination, Mawi’s iSWAB-RNA v2 collection technology and MagBio Genomics’ purification chemistry provide an efficient workflow for high throughput purification of high-quality RNA for demanding downstream applications.
About MagBio Genomics Inc.
MagBio Genomics is a global company that develops and commercializes magnetic bead-based products for nucleic acid isolation including biomarkers as tools for liquid biopsy genomic research. The current focus encompasses products that cover the complete sample preparation for NGS; from allowing safeguarding integrity of bio-samples, efficient isolation of circulating biomarkers to target enrichment from biological samples. Products are applied to human genetic research including cancer genomic studies and non-invasive prenatal testing (NIPT).“WE SIMPLY MAKE NGS BETTER.” For more information, visit http://www.magbiogenomics.com .
About Mawi DNA Technologies
Mawi DNA Technologies has developed and commercialized the iSWAB technology, an innovative system for collection of biosamples. Flagship product iSWAB-DNA has gained significant market traction due to its ability to be used for animals and all human population segments from infants to the elderly, with robust DNA yield and low bacterial DNA content. Mawi DNA has established relationships with children’s hospitals for neonatal screening and has an extensive global network of international distributors to market and sell iSWAB products. For more information, visit http://www.mawidna.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210511005456/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Promega Receives SBTi Validation for Near-Term Science-Based Emissions Reduction Targets9.6.2026 13:01:00 CEST | Press release
Validated targets cover Scope 1, 2 and 3 emissions, including a supplier engagement commitment reaching 67% of suppliers by spend by 2030 Promega Corporation has received approval from the Science Based Targets initiative for its near-term emissions reduction targets, developed to reflect the current status of climate science. SBTi is a corporate climate organization that develops standards, tools and guidance for setting greenhouse gas emissions reductions targets in line with what is needed to avoid the worst impacts of climate change. “These goals aren’t just a commitment, they represent a verified plan with third-party accountability built in,” says Corey Meek, Corporate Responsibility Program Manager at Promega. “Our SBTi-validated targets reflect a comprehensive understanding of our greenhouse gas emissions across our entire value chain and set a clear, science-aligned standard for what we aim to achieve by 2030.” The Science Based Targets initiative has approved the following ne
IFF’s 2025 Do More Good Report Highlights Progress in Nature-Based Innovation9.6.2026 13:00:00 CEST | Press release
Driving growth for high-performance, sustainable solutions, while enabling customers to avoid 27.2 million metric tons of CO₂e emissions IFF (NYSE: IFF) — a global leader in flavors, fragrances, food ingredients and health & biosciences — released its 2025 Do More Good Report, highlighting the company’s commitment to creating better products and experiences for people and the planet. IFF’s increasingly nature-based portfolio underscores the central role of sustainability and positions its innovation at the intersection of biology and chemistry. Through continued investment in R&D, expanded global innovation partnerships and measurable impact across the value chain, the report demonstrates how IFF is reducing environmental impact while delivering differentiated performance and long-term value for customers and consumers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608586967/en/ Cover image for IFF’s 2025 Do More Good re
Icon Solutions Showcases How Banks Can Accelerate Digital Asset Innovation with IPF9.6.2026 11:30:00 CEST | Press release
Banks can now deploy digital asset payments faster, without risking fragmentation Icon Solutions – the UK fintech enabling banks to design and implement state-of-the-art payment systems – has released a reference implementation showing how banks can use the Icon Payments Framework (IPF) to accelerate support for payments processing using distributed ledger technology (DLT)-based digital assets. As IPF is agnostic to both the type of digital asset and the DLT network on which they are issued, the risk of fragmentation is reduced as adoption scales. There is growing momentum for digital assets such as stablecoins, tokenised deposits, deposit tokens and central bank digital currencies (CBDCs) to enable faster, cheaper and smarter payments. Yet the emergence of different digital asset types and DLT networks – which must also work with existing financial infrastructure – creates fragmentation and operational complexity for banks. This is compounded by legacy vendor solutions that limit choi
monday.com Appoints Ben Barnett General Manager of EMEA to Drive Next Phase of Regional Growth9.6.2026 10:00:00 CEST | Press release
In 2025, monday.com saw 26% YoY revenue growth in EMEABarnett will be a driving force in monday.com’s biggest transformation yet monday.com (Nasdaq: MNDY), the AI work platform that turns strategy into execution at scale, today announced Ben Barnett’s appointment to General Manager (GM) of Europe, the Middle East and Africa, marking a major milestone in the company’s global expansion. Ben, who has been with monday.com for five years, brings a decade of experience in senior B2B sales roles at software companies and has overseen significant, sustained growth at monday.com in the UK and Ireland since joining in 2021. In his new position, Ben’s priorities include delivering the monday.com’s EMEA go-to-market strategy, fostering key partnerships, and bolstering its newly announced AI work platform. He is based in London. Ben’s promotion comes as monday.com builds on a period of rapid regional success, with EMEA revenue up 26% year-on-year in 2025. Last year, monday.com expanded its regional
Interactive Brokers Launches Commission-Free iShares ETFs from BlackRock through Recurring Investment Feature Across Europe9.6.2026 10:00:00 CEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of Commission-Free ETFs within its Recurring Investment feature for eligible individual investors across the European Economic Area. Investors can now access more than 500 commission-free iShares ETFs from BlackRock spanning a broad range of asset classes and strategies, including bonds, equities, themes and sectors. The iShares ETFs available on the IBKR platform give individual investors an accessible, cost-efficient way to build well-diversified portfolios. Since investors pay no trading commissions, more of their capital stays invested and compounding over time, while a broad selection of funds across asset classes makes it straightforward to construct and rebalance portfolios. iShares ETFs are available commission-free through IBKR's Recurring Investments feature, allowing investors to automate their periodic ETF contributions. Clients can select individual ETFs or ETF portfolios, set a cont
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom